|
|
Article: Alcon will pay up to $589M for ESBATech.
- Article from:
- M2 Presswire
- Article date:
- September 15, 2009
CopyrightCOPYRIGHT 2009 Normans Media Ltd. This material is published under license from the publisher through the Gale Group, Farmington Hills, Michigan. All inquiries regarding rights should be directed to the Gale Group. (Hide copyright information)
|
M2 PRESSWIRE-15 September 2009-Crown Equity Holdings, Inc.: Alcon will pay up to $589M for ESBATech(C)1994-2009 M2 COMMUNICATIONS
RDATE:14092009
Las Vegas CRWENews.com is pleased to announce a stock highlight on Alcon Inc. (ACL) Eye-drug maker Alcon said Monday September 14, 2009 it will buy Swiss biotechnology company ESBATech AG in a deal worth up to $589 million.
Alcon said it will pay $150 million in cash, with milestone payments of up to $439 million if ESBATech drug candidates advance through clinical development. ESBATech is a development-stage company with no products on the market, but is working on treatments for inflammatory eye ...
Related newspaper, magazine, and journal articles:
|
|
Article: Crown Equity Holdings Terminates Agreement ...
M2 Presswire;
March 23, 2009 ;
507 words
...M2 PRESSWIRE-23 March 2009-Crown Equity Holdings, Inc.: Crown Equity Holdings Terminates Agreement to Acquire Alpha ... LTD RDATE:20032009 Las Vegas, NV - Crown Equity Holdings, Inc. (OTC Bulletin Board: CRWE ...
|
|